



## Board of Directors – 2023 Operational Summary

Date	Resolutions
023/01/31	<ul style="list-style-type: none"> <li>• Proposal to authorize the reporting for audit report and audit tracking report.</li> <li>• Proposal to renew loan agreement with financial institution.</li> <li>• Proposal to provide a loan guarantee to TWi Pharmaceutical Inc., a company that is 100% owned by the Company.</li> <li>• Proposal to ratify the Bora Biologics Inc's manager, the Company's subsidiary.</li> <li>• Proposal to discharge the Company's manager's non-compete clause.</li> <li>• Proposal to discharge the Company's director's non-compete clause.</li> <li>• Proposal to issue project bonus for manager.</li> <li>• 2022 First Employee Stock Warrant for TWi Pharmaceutical for the Company's manager.</li> <li>• Proposal to report to Frank Chen as the Company's information security manager.</li> </ul>
2023/03/16	<ul style="list-style-type: none"> <li>• The Company's 2022 Statement on Internal Control.</li> <li>• The Company to change CPA due to accounting firm's internal CPA rotation.</li> <li>• Evaluation on the Company CPA's independence and competence.</li> <li>• 2022 Business Operation Report and Financial Statements.</li> <li>• 2022 Surplus Distribution in the form of Cash Dividend.</li> <li>• Distribute new shares for capital increase by earnings.</li> <li>• Status for the Company's 2nd domestic unsecured convertible corporate bonds.</li> <li>• Proposal to issue employee stock warrants.</li> <li>• Proposal to formulate the record date of cash capital increase for the Company's 2020 employee stock warrant exercised on 2023 Q1.</li> <li>• Proposal to issue the Company's 3rd domestic unsecured convertible corporate bonds.</li> <li>• Proposal to renew loan agreement with financial institution</li> <li>• Re-election of directors.</li> <li>• Nomination of directors and independent directors.</li> <li>• Proposal to discharge newly elect director and their representatives' non-compete clause.</li> <li>• Proposal to amend "Articles of Incorporation", "Rule of Procedure for Shareholder's Meeting", "Procedure for Election for Director" and other procedure.</li> <li>• Proposal to amend the Company's "2022 Stock Repurchase and Transfer to Employee Program" and "Ethical Corporate Management Best Practice Principle".</li> </ul>

	<ul style="list-style-type: none"> <li>• Proposal to amend “Procedure for Loaning Funds”, “Procedure for Acquisition and Disposal of Assets”, “Procedure for Engaging Financial Derivative Transaction”, and other procedure.</li> <li>• Proposal to amend “Internal Control Procedure”, “Authorization Table”, “Internal Control Implementation Guideline”, “Internal Control Evaluation Procedure”, “Group, Specific Company’s Transaction with Related Party”, and other procedure.</li> <li>• Proposal to amend “Corporate Governance Best Practice Principle”, “Procedure for Board of Director Meeting”, “Operating Procedure for Handling Director’s Request”, “Rules Governing Financial and Business Matters Between the Company and its Affiliate” and other procedures.</li> <li>• The Company’s Board of Director’s resolution on 2023 stockholder meeting and related item.</li> <li>• Proposal to amend “Remuneration Committee Charter”.</li> <li>• 2022 Employees’ and Directors’ Compensation.</li> <li>• 2022 directors compensation distribution detail.</li> <li>• 2022 employee remuneration distribution detail for managerial personnel.</li> <li>• The Company’s managerial personnel 2022 remuneration raise</li> </ul>
2023/05/12	<ul style="list-style-type: none"> <li>• The Company’s Board of Director’s resolution on the Company’s 2023 Q1 financial statement.</li> <li>• Proposal to renew loan agreement with financial institution.</li> <li>• Proposal for the Company and subsidiary Bora Pharmaceutical Laboratories Inc. to jointly donate and establish “Bora Sheng Wei En Foundation”.</li> <li>• Proposal to revise “Director’s remuneration and bonus distribution policy”.</li> <li>• Proposal to transfer Tom Chang, the vice president for the manufacturing, to the Company and promote to senior vice president.</li> <li>• Proposal to nominate Debbie Chang, Taiwan’s vice president for quality operation, as the Company’s manager</li> </ul>
2023/06/06	<ul style="list-style-type: none"> <li>• To nominate the chairman of the board</li> </ul>
2023/06/27	<ul style="list-style-type: none"> <li>• Proposal to nominate the Company’s fifth term remuneration committee member.</li> <li>• Proposal to nominate the Company’s second term sustainable development committee member.</li> <li>• To authorize the Company’s Board of Director’s resolution on ex-rights date and the price adjustment for the employee stock warrant and the Company’s 2nd domestic unsecured convertible corporate bonds.</li> <li>• Proposal to formulate the record date of cash capital increase for the Company’s 2020 employee stock warrant exercised on 2023 Q2 and the Company’s 2nd domestic unsecured convertible corporate bonds.</li> </ul>

	<ul style="list-style-type: none"> <li>• Proposal to renew loan agreement with financial institution.</li> <li>• Proposal to provide a loan guarantee amounted to NTD 240 million to subsidiary Bora Biologics Co., Ltd.</li> <li>• To revise the Company's 2022 First Employee Stock Warrant Plan</li> </ul>
2023/07/13	<ul style="list-style-type: none"> <li>• Proposal to renew loan agreement with financial institution.</li> <li>• The Company proposes to give up the cash capital increase for its subsidiary Bora Health Inc.</li> <li>• Proposal to issue new shares from cash capital increase from Bora Health Inc.'s to manager.</li> <li>• Proposal to issue new shares from cash capital increase from Bora Health Inc.'s to non-manager</li> </ul>
2023/08/14	<ul style="list-style-type: none"> <li>• The Company's Board of Director's resolution on the Company's 2023 Q2 financial statement.</li> <li>• Proposal to distribute the Company's earnings for the first half of 2023.</li> <li>• Proposal to submit the contingent price adjustment in accordance to the 2023Q2 review financial statement.</li> </ul>
2023/08/17	<ul style="list-style-type: none"> <li>• Proposal for subsidiary TWi Pharmaceuticals, Inc. to purchase drug certificate from Almatica/Alvogen Group.</li> </ul>
2023/08/21	<ul style="list-style-type: none"> <li>• Proposal for the share conversion and authorization signing agreement between the subsidiary Bora Health Inc. and SunWay Biotech Co., Ltd.</li> <li>• Proposal to renew loan agreement with financial institution.</li> </ul>
2023/09/19	<ul style="list-style-type: none"> <li>• The Company's stock listing application.</li> <li>• The Company's statement on internal control from July 1, 2022 to June 30, 2023.</li> <li>• The Company's financial forecast from 112Q4 to 113Q1.</li> <li>• The Company's corporate governance self-assessment report for stock listing.</li> <li>• To revise the Company's accounting system.</li> <li>• Proposal to issue project bonus for manager.</li> <li>• Proposal to issue the Company's 2023 first employee stock warrants to manager.</li> <li>• Proposal to issue the Company's 2023 first employee stock warrants to non-manager.</li> </ul>
2023/11/09	<ul style="list-style-type: none"> <li>• The Company's Board of Director's resolution on the Company's 2023 Q3 financial statement.</li> <li>• Propose to sign loan agreement with financial institution.</li> <li>• Proposal to formulate the record date of cash capital increase for the Company's 2020 employee stock warrant exercised on 2023 Q3 and the Company's 2nd domestic unsecured convertible corporate bonds.</li> </ul>



	<ul style="list-style-type: none"><li>• Proposal to issue the Company's 2023 first employee stock warrants to non-manager.</li><li>• Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program"</li></ul>
2023/12/19	<ul style="list-style-type: none"><li>• The Company's 2024 operating plan.</li><li>• The Company's 2024 budget.</li><li>• The Company's 2024 internal audit plan.</li><li>• Propose to sign loan agreement with financial institution.</li><li>• The Company's ESG material issue and management policy.</li><li>• Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program".</li><li>• Proposal for the Company's 2023 year-end performance bonus distribution.</li></ul>